Revolutionizing Immunotherapy with VHH Technology. Our proprietary next generation nano-link technology platform uses state of the art Bioinformatics to guide lead candidate selection. Rapid path from discovery to lead candidate selection in less than 6 months and to IND filing in (24 months); preclinical proof of concept demonstrated. Lead program well positioned for breakthrough therapy designation. Our lead program is a PD-1/CTLA4 bi-specific VHH with a differentiated TPP that provides superior efficacy and safety compared to SOC. We have assembled a highly qualified team of industry veterans with broad & deep drug development experience across multiple therapeutic areas, including oncology and inflammatory diseases. We have a proven track record of successfully developing and commercializing blockbuster therapeutic products like Yervoy, Opdivo, Velcade. We have a Strong IP position and have established strategic collaborations with Tufts University, University of Chicago and University of Pittsburg. Our value proposition is driven by our novel nano-link technology platform. Clinically validated target-based approach to minimize risk of failure. Highly differentiated products which have the potential to be best in Class and most importantly a highly accomplished drug development team that understands the regulatory environment with a proven track record of taking drugs from an IND to NDA approval.www.vicerobio.com

Strategic consultant advising Senior Leadership resulting in approvals of Copiktra, Xpovio and Tazverik.

Discovery Medicine Clinical Pharmacology, Oncology, Virology